BAX Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population derived from the HAP1 near-haploid human cell line. This product features targeted disruption of the BAX gene, eliminating functional BAX protein and generating a loss-of-function model for intrinsic apoptosis studies. The polyclonal format retains a heterogeneous mix of editing events, offering a practical and robust tool for functional genomics without requiring single-cell cloning. The cells provide a genetically tractable system to investigate BAX-dependent signaling networks.
The HAP1 cell line originates from the KBM-7 chronic myeloid leukemia line and retains a near-haploid karyotype. This genetic simplicity eliminates allelic redundancy, enabling direct phenotype interpretation after gene disruption. HAP1 cells display rapid proliferation and have become a mainstream host for CRISPR-based knockout screening. Their CML lineage offers a relevant oncogenic context for apoptosis research, and the near-haploid state ensures consistent editing outcomes in polyclonal populations, making them ideal for pathway dissection and drug sensitivity profiling.
BAX is a pro-apoptotic Bcl-2 family protein that drives mitochondrial outer membrane permeabilization (MOMP) in response to cellular stress. Activated upstream by BH3-only regulators BIM, BID, PUMA, NOXA, and HRK, often under p53 transcriptional control, BAX oligomerizes with BAK and tBID to release cytochrome c. This triggers APAF?1/caspase?9 apoptosome formation and subsequent caspase?3 cleavage, culminating in PARP proteolysis and cell death. Anti-apoptotic partners BCL?2, BCL?XL, and MCL?1 neutralize BAX by direct binding or BH3 sequestration. At the mitochondrial surface, BAX interacts with VDAC1, linking apoptotic machinery to channel-dependent permeability changes.
Disruption of BAX in HAP1 cells abrogates the intrinsic apoptotic cascade, rendering the cells resistant to diverse cytotoxic insults that converge on mitochondria. DNA-damaging agents, kinase inhibitors, or p53-activating compounds fail to trigger cytochrome c release or downstream caspase activation. This phenotype creates a powerful platform for distinguishing BAX-dependent versus BAX-independent death pathways and for studying alternative cell death modalities. The near-haploid background ensures that knockout effects are fully penetrant, enabling clear dissection of signal rewiring and synthetic lethal relationships.
Applications span apoptosis mechanism studies, cancer drug resistance screening, mitochondrial dysfunction analysis, and functional genomics. Western blotting and flow cytometry (annexin V/PI) are routinely employed to assess protein expression and cell death commitment. Caspase-3/7 activity and JC-1 mitochondrial membrane potential assays provide quantitative functional readouts. RT?qPCR monitors transcriptional changes in pro?apoptotic genes, while MTT viability assays enable dose?response testing. The model is particularly useful for validating BH3 mimetic efficacy and investigating ischemia-reperfusion or neurodegenerative stress pathways. For further information, contact Ascent Research.
